Gamida Cell Ltd. (NASDAQ:GMDA) Shares Bought by ARK Investment Management LLC

ARK Investment Management LLC raised its stake in Gamida Cell Ltd. (NASDAQ:GMDA) by 51.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,144,422 shares of the company’s stock after acquiring an additional 724,806 shares during the quarter. ARK Investment Management LLC owned approximately 2.03% of Gamida Cell worth $885,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Stonepine Capital Management LLC lifted its holdings in Gamida Cell by 431.1% in the third quarter. Stonepine Capital Management LLC now owns 7,965,865 shares of the company’s stock valued at $8,205,000 after acquiring an additional 6,465,865 shares during the period. Federated Hermes Inc. increased its position in shares of Gamida Cell by 17.5% in the first quarter. Federated Hermes Inc. now owns 5,128,300 shares of the company’s stock valued at $21,282,000 after buying an additional 764,985 shares in the last quarter. FMR LLC increased its position in shares of Gamida Cell by 0.9% in the second quarter. FMR LLC now owns 4,630,125 shares of the company’s stock valued at $8,195,000 after buying an additional 42,421 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Gamida Cell by 12.8% in the first quarter. JPMorgan Chase & Co. now owns 731,328 shares of the company’s stock valued at $3,035,000 after buying an additional 83,009 shares in the last quarter. Finally, Mariner LLC increased its position in shares of Gamida Cell by 8.3% in the first quarter. Mariner LLC now owns 621,334 shares of the company’s stock valued at $2,579,000 after buying an additional 47,587 shares in the last quarter. 50.34% of the stock is owned by institutional investors and hedge funds.

Gamida Cell Stock Down 82.7 %

NASDAQ GMDA opened at $0.06 on Thursday. The business has a fifty day moving average price of $0.36 and a 200 day moving average price of $0.51. Gamida Cell Ltd. has a one year low of $0.05 and a one year high of $2.51. The company has a debt-to-equity ratio of 213.14, a current ratio of 3.32 and a quick ratio of 3.20.

Analysts Set New Price Targets

A number of analysts have recently commented on GMDA shares. JMP Securities restated a “market perform” rating on shares of Gamida Cell in a research report on Monday, January 29th. Needham & Company LLC restated a “buy” rating and issued a $6.00 price objective on shares of Gamida Cell in a research report on Tuesday, December 5th.

Gamida Cell Company Profile

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia.